INP105

COMBINATION_PRODUCT2 trials

Sponsors

Impel Pharmaceuticals

Conditions

Acute AgitationAgitation in Adolescents and Young Adults With ASD

Phase 1

Safety and Tolerability of INP105 (Olanzapine by I231 POD® Device) Nasal Spray in Healthy Volunteers - SNAP 101

CompletedNCT03624322

Impel PharmaceuticalsAcute Agitation

Start: 2018-08-05End: 2018-10-03Updated: 2018-10-04

Phase 2

INP105 Proof-of-concept Study for the Acute Treatment of Agitation in Adolescents and Young Adults With ASD

TerminatedNCT05163717

Impel PharmaceuticalsAgitation in Adolescents and Young Adults With ASD

Start: 2022-06-23End: 2023-04-24Updated: 2023-09-28

Related Papers

The SNAP 101 Double-Blind, Placebo/Active-Controlled, Safety, Pharmacokinetic, and Pharmacodynamic Study of INP105 (Nasal Olanzapine) in Healthy Adults

The Journal of Clinical Psychiatry2020-06-3021 citations